10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis
USA - NASDAQ:TXG - US88025U1097 - Common Stock
13.77 USD
+0.41 (+3.07%)
13.77 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to TXG. TXG was compared to 57 industry peers in the Life Sciences Tools & Services industry. While TXG has a great health rating, there are worries on its profitability. While showing a medium growth rate, TXG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TXG has reported negative net income.
In the past year TXG had a positive cash flow from operations.
TXG had negative earnings in each of the past 5 years.
TXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TXG's Return On Assets of -8.63% is in line compared to the rest of the industry. TXG outperforms 49.12% of its industry peers.
With a Return On Equity value of -10.94%, TXG perfoms like the industry average, outperforming 52.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.63% | ||
| ROE | -10.94% | ||
| ROIC | N/A |
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TXG's Gross Margin of 69.50% is amongst the best of the industry. TXG outperforms 94.74% of its industry peers.
TXG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXG has more shares outstanding
Compared to 5 years ago, TXG has more shares outstanding
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 3.55 indicates that TXG is not in any danger for bankruptcy at the moment.
TXG has a better Altman-Z score (3.55) than 64.91% of its industry peers.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.55 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
TXG has a Current Ratio of 5.84. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.84, TXG belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
A Quick Ratio of 5.23 indicates that TXG has no problem at all paying its short term obligations.
TXG's Quick ratio of 5.23 is fine compared to the rest of the industry. TXG outperforms 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.84 | ||
| Quick Ratio | 5.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 61.39% over the past year.
TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 2.02%.
The Revenue has been growing by 19.96% on average over the past years. This is quite good.
EPS 1Y (TTM)61.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.5%
Revenue 1Y (TTM)2.02%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%12.93%
3.2 Future
The Earnings Per Share is expected to grow by 15.77% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.18% on average over the next years.
EPS Next Y60.27%
EPS Next 2Y16.99%
EPS Next 3Y16.51%
EPS Next 5Y15.77%
Revenue Next Year2.03%
Revenue Next 2Y0.18%
Revenue Next 3Y3.41%
Revenue Next 5Y4.18%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, TXG is valued a bit cheaper than 77.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.14 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TXG's earnings are expected to grow with 16.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.99%
EPS Next 3Y16.51%
5. Dividend
5.1 Amount
No dividends for TXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.77
+0.41 (+3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.25%
Inst Owner Change-0.78%
Ins Owners1.65%
Ins Owner Change0.92%
Market Cap1.71B
Revenue(TTM)644.47M
Net Income(TTM)-84601000
Analysts73.04
Price Target15.3 (11.11%)
Short Float %15.45%
Short Ratio6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.48%
Min EPS beat(2)24.36%
Max EPS beat(2)174.61%
EPS beat(4)3
Avg EPS beat(4)44.4%
Min EPS beat(4)-34.43%
Max EPS beat(4)174.61%
EPS beat(8)5
Avg EPS beat(8)16.13%
EPS beat(12)7
Avg EPS beat(12)12.99%
EPS beat(16)8
Avg EPS beat(16)2.08%
Revenue beat(2)2
Avg Revenue beat(2)19.28%
Min Revenue beat(2)15.77%
Max Revenue beat(2)22.78%
Revenue beat(4)3
Avg Revenue beat(4)8.93%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)22.78%
Revenue beat(8)5
Avg Revenue beat(8)4.38%
Revenue beat(12)9
Avg Revenue beat(12)3.89%
Revenue beat(16)11
Avg Revenue beat(16)2.52%
PT rev (1m)0%
PT rev (3m)10.8%
EPS NQ rev (1m)0.39%
EPS NQ rev (3m)1.16%
EPS NY rev (1m)11.13%
EPS NY rev (3m)50.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)4.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.66 | ||
| P/FCF | 30.14 | ||
| P/OCF | 25.6 | ||
| P/B | 2.22 | ||
| P/tB | 2.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)0.46
FCFY3.32%
OCF(TTM)0.54
OCFY3.91%
SpS5.18
BVpS6.21
TBVpS6.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.63% | ||
| ROE | -10.94% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.5% | ||
| FCFM | 8.83% |
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score6
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 22.39% | ||
| Cap/Sales | 1.56% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.84 | ||
| Quick Ratio | 5.23 | ||
| Altman-Z | 3.55 |
F-Score6
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)221.05%
Cap/Depr(5y)283.34%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.5%
EPS Next Y60.27%
EPS Next 2Y16.99%
EPS Next 3Y16.51%
EPS Next 5Y15.77%
Revenue 1Y (TTM)2.02%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%12.93%
Revenue Next Year2.03%
Revenue Next 2Y0.18%
Revenue Next 3Y3.41%
Revenue Next 5Y4.18%
EBIT growth 1Y33.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.27%
EBIT Next 3Y19.1%
EBIT Next 5Y15.24%
FCF growth 1Y148.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y682.7%
OCF growth 3YN/A
OCF growth 5Y-28.08%
10X GENOMICS INC-CLASS A / TXG FAQ
Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?
ChartMill assigns a fundamental rating of 4 / 10 to TXG.
What is the valuation status for TXG stock?
ChartMill assigns a valuation rating of 1 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.
Can you provide the profitability details for 10X GENOMICS INC-CLASS A?
10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.